8-KMaterial AgreementsOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jan 15, 2019)

Filed January 15, 2019For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant capital raise through an underwritten public offering of its common stock, as detailed in this Form 8-K filing dated January 15, 2019. The company entered into an Underwriting Agreement with Barclays Capital Inc. to sell 5,000,000 shares at an offering price of $77.50 per share. This offering is expected to generate approximately $382 million in net proceeds for Alnylam, after accounting for underwriting discounts and estimated expenses. The proceeds from this offering will provide the company with additional financial flexibility, likely to support its ongoing research and development activities, clinical trials, and potential commercialization efforts for its RNAi therapeutics pipeline. Investors should note the potential for an additional 750,000 shares to be sold to cover over-allotments.

Key Highlights

  • 1Alnylam Pharmaceuticals entered into an underwriting agreement for a public offering of 5,000,000 shares of common stock.
  • 2The offering price is set at $77.50 per share.
  • 3The company expects to receive approximately $382 million in net proceeds from the offering.
  • 4An option is granted to the underwriter to purchase up to an additional 750,000 shares to cover over-allotments.
  • 5The offering is being conducted under an existing shelf registration statement filed in May 2017.
  • 6The offering is expected to close on January 17, 2019, subject to customary closing conditions.
  • 7A press release announcing the pricing of the offering was also filed.

Frequently Asked Questions

While not explicitly stated in the 8-K, such offerings are typically conducted to raise capital to fund research and development, clinical trials, manufacturing, potential commercialization of drugs, or for general corporate purposes. For Alnylam, this likely supports its pipeline of RNAi therapeutics.

Alnylam expects to receive approximately $382 million in net proceeds from the sale of 5,000,000 shares, after deducting underwriting discounts and estimated offering expenses. This amount could increase if the underwriter exercises its option to purchase additional shares.

The over-allotment option allows the underwriter (Barclays Capital Inc.) to purchase up to an additional 750,000 shares from Alnylam at the same offering price. This option is typically used to stabilize the stock price in the secondary market after the offering and can provide Alnylam with additional capital if exercised.

The offering is expected to close on January 17, 2019, provided that all customary closing conditions are satisfied.